The biological-age score is one part of the record. Explore the individual blood-marker changes, the documented plan and the separately labelled account in EVA’s published PDF.
D.S., male, 44, had favourable baseline metabolic markers alongside cardiovascular, inflammatory and liver markers that warranted attention. The detailed case record covers March to July 2025, four months. During that period, ApoB fell from 90 to 62 mg/dL, homocysteine from 17.3 to 7.17 µmol/L and hs-CRP from 1.75 to 0.32 mg/L.
See the measurements behind the age score
D.S.’s record shows ApoB, homocysteine, inflammation and liver-marker results together. Keeping those measurements visible makes the biological-age headline easier to interpret. The KDM-13 case record and PhenoAge PDF remain separate accounts with their own model labels and observation windows.
Starting point and context
AST fell from 58 to 27 U/L and LDL from 129.3 to 85 mg/dL. HDL rose from 52.1 to 62.2 mg/dL. The source also records an adjusted hormonal protocol, with estradiol falling from 83.1 to 38.73 pg/mL and FT3 from 0.46 to 0.37 ng/dL. His baseline HOMA-IR was 0.56. The oral protocol included lipid and methylation support, alongside other individually selected supplements.
Explore EVA blood biomarker testing
The recorded results
| Biomarker | Mar 2025 | Jul 2025 | Change |
|---|---|---|---|
| Cardiovascular & Lipids | |||
| ApoB (mg/dL) | 90 | 62 | −31% |
| LDL (mg/dL) | 129.3 | 85 | −34% |
| HDL (mg/dL) | 52.1 | 62.2 | +19% |
| Total Cholesterol (mg/dL) | 192 | 156 | −19% |
| Triglycerides (mg/dL) | 53 | 44 | −17% |
| TG/HDL ratio | 1.02 | 0.71 | Optimal |
| Inflammation & Liver | |||
| hs-CRP (mg/L) | 1.75 | 0.32 | −82% |
| AST (U/L) | 58 (H) | 27 | −53% |
| ALT (U/L) | 36 | 23 | −36% |
| Nutrition & Methylation | |||
| Homocysteine (µmol/L) | 17.30 (H) | 7.17 | −59% |
| Folate (ng/mL) | 32.97 | 21.16 | Titrated |
| Vitamin D (ng/mL) | 46.48 | 43.59 | Stable |
| Hormonal (adjusted protocol) | |||
| Estradiol E2 (pg/mL) | 83.1 (H) | 38.73 | −53% |
| FT3 (ng/dL) | 0.46 (H) | 0.37 | Normalised |
| Biological Age | |||
| KDM-13 Biological Age | 41.7 yrs | 30.9 yrs | −10.8 yrs |
Figures are reproduced from the case record, including qualitative entries and reported percentage changes. Source labels such as optimal describe the case’s interpretation, not a universal reference range. A dash indicates a value not supplied.
Context that matters
- KDM-13 is explicitly the model used for 41.7 to 30.9 years, a 10.8-year reduction. At the reported chronological age of 44, the follow-up score was 13.1 years below calendar age; this is a score comparison, not a lifespan forecast.
- The original describes EVA’s KDM-13 implementation using 13 blood markers: albumin, ALP, CRP, cholesterol, HbA1c, BUN, uric acid, WBC, lymphocytes, MCV, RDW, glucose and RBC.
- The public PDF companion appears to describe the same case, based on closely matching biomarker values. It uses a different model and observation label: PhenoAge 44 to 31.5 years, January–July 2025, six months. It is included as a companion account rather than an additional participant; it does not establish independently confirmed blood draws or explicit identity.
- The two source documents give different starting months. Their source-labelled windows are retained rather than silently reconciled. The detailed table above follows the March–July case record.
The recorded protocol
The following items are recorded in this person’s plan. This is a historical description, not a protocol for readers to copy.
- Berberine (ApoB, LDL)
- Bergamot BPF (lipids, ApoB)
- Omega-3 (CRP, HDL, triglycerides)
- TMG (methylation, homocysteine)
- B12 Methylcobalamin sublingual
- L-Methylfolate sublingual
- Vitamin D3+K2 drops
- Magnesium Bisglycinate
- Boron
- Zinc Bisglycinate + Copper
Learn about personalised supplements
What remained in progress
The record demonstrates several marker changes within one person’s follow-up. It does not establish a measured reduction in heart attacks or dementia, and it cannot isolate the effect of any individual supplement. Continued clinician-led review remains the appropriate way to interpret the markers together.
Reading the biological-age result
Biological-age scores are model outputs derived from the inputs available to that model. A lower score is not a measured gain in lifespan. Different models use different inputs and should be labelled and interpreted separately.
The published PDF account
EVA’s published PDF describes a 44-year-old executive during a January–July 2025 observation period. It reports a PhenoAge change from 44 to 31.5 years over six months, a 12.5-year reduction in that score. This is separate from the KDM-13 result and March–July window in the detailed case record above.
The PDF reports the same ApoB, hs-CRP, homocysteine, AST and triglyceride pairs, with LDL and HDL rounded. It appears to describe the same case and is included here as a companion account, rather than a separate case study. The PDF does not print the client’s initials; the association is based on that closely matching biomarker pattern. The differing observation windows are retained as each source gives them.
| Measure | Baseline | After six months |
|---|---|---|
| PhenoAge | 44 years | 31.5 years |
| ApoB | 90 mg/dL | 62 mg/dL |
| hs-CRP | 1.75 mg/L | 0.32 mg/L |
| Homocysteine | 17.3 µmol/L | 7.17 µmol/L |
| AST | 58 U/L | 27 U/L |
| LDL-C | 129 mg/dL | 85 mg/dL |
| HDL-C | 52 mg/dL | 62 mg/dL |
| Triglycerides | 53 mg/dL | 44 mg/dL |
Testing and the recorded plan
The PDF describes a 72-marker assessment, PhenoAge modelling and OmicsEdge genetic analysis covering more than 200 million variants. It names MTHFR, CUBN, PEMT and TCF7L2 findings and describes population-typical polygenic risk scores for type 2 diabetes, coronary artery disease and Alzheimer’s disease. These are statements from the PDF account, not additional genetic findings newly verified for this page.
The nutrition plan reduced refined carbohydrates and included adequate protein, fibre and healthy fats. The PDF lists methylated B complex, methylfolate (5-MTHF), TMG, EPA/DHA omega-3, berberine, vitamin K2D, zinc, copper, vitamin C, N-acetyl cysteine and magnesium glycinate. This PDF-specific list is kept distinct from the supplement list in the detailed case record.
What the client reported
The PDF reports clearer thinking and concentration, more stable daily energy, fewer energy crashes, improved stress resilience, stronger gym performance, better endurance and recovery, and improved productivity. These were client-reported experiences, not independently measured outcomes in the biomarker table.
Why are two different biological-age reductions shown for this case?
The detailed case record reports KDM-13 41.7 to 30.9 over March–July 2025. The published PDF reports PhenoAge 44 to 31.5 over January–July 2025. These model scores and source windows are different and should be read separately.
How this connects to EVA
EVA connects blood testing, clinician-reviewed personalised supplements and follow-up. Blood Intelligence uses your blood results; Elite DNA + Blood adds genetic information. DNA is optional. The aim is a personal plan grounded in your information, with review as new results become available.
Look beyond a single score
If a biological-age result has caught your attention, start by understanding the blood information and clinical context behind it.
See how to start with EVAExplore blood testing, optional DNA and personalised supplements, with the current steps to get started in Dubai.
This is an individual observational case, not a controlled trial. Biomarker changes and biological-age scores do not establish the effect of a particular supplement, predict an individual’s lifespan or guarantee future results. The protocol described was personalised and is not a recommendation to self-prescribe. EVA supports informed health decisions and is not intended to diagnose, treat, cure or prevent disease. Consult a qualified healthcare provider for medical advice.
Source: EVA clinical case record supplied for publication. Observation dates and model names are shown in the case. Prepared for web publication in October 2026.